Cyclerion Therapeutics Inc - ESG Rating & Company Profile powered by AI
Other companies in the rating industry group for Cyclerion Therapeutics Inc are shown. This assessment of Cyclerion Therapeutics Inc uses intelligence from across the web and also from available documents by Cyclerion Therapeutics Inc. The analysis of Cyclerion Therapeutics Inc is assembled by All Street Sevva using leading Cognitive Robots.
Cyclerion Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.9; made up of an environmental score of 0.0, social score of 1.6 and governance score of 4.0.
1.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1608 | Agios Pharmaceuticals Inc | 2.0 | Medium |
1608 | Unrivaled Brands Inc | 2.0 | Medium |
... | ... | ... | |
1617 | Cyclerion Therapeutics Inc | 1.9 | Low |
1617 | Celsion Corp | 1.9 | Low |
1617 | Ainos Inc | 1.9 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Cyclerion Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Cyclerion Therapeutics Inc disclose current and historical energy intensity?
Does Cyclerion Therapeutics Inc report the average age of the workforce?
Does Cyclerion Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Cyclerion Therapeutics Inc disclose its ethnicity pay gap?
Does Cyclerion Therapeutics Inc disclose cybersecurity risks?
Does Cyclerion Therapeutics Inc offer flexible work?
Does Cyclerion Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Cyclerion Therapeutics Inc disclose the number of employees in R&D functions?
Does Cyclerion Therapeutics Inc conduct supply chain audits?
Does Cyclerion Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Cyclerion Therapeutics Inc conduct 360 degree staff reviews?
Does Cyclerion Therapeutics Inc disclose the individual responsible for D&I?
Does Cyclerion Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Cyclerion Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Cyclerion Therapeutics Inc disclose water use targets?
Does Cyclerion Therapeutics Inc have careers partnerships with academic institutions?
Did Cyclerion Therapeutics Inc have a product recall in the last two years?
Does Cyclerion Therapeutics Inc disclose incidents of discrimination?
Does Cyclerion Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Cyclerion Therapeutics Inc issued a profit warning in the past 24 months?
Does Cyclerion Therapeutics Inc disclose parental leave metrics?
Does Cyclerion Therapeutics Inc disclose climate scenario or pathway analysis?
Does Cyclerion Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Cyclerion Therapeutics Inc disclose the pay ratio of women to men?
Does Cyclerion Therapeutics Inc support suppliers with sustainability related research and development?
Does Cyclerion Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Cyclerion Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Cyclerion Therapeutics Inc involved in embryonic stem cell research?
Does Cyclerion Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Cyclerion Therapeutics Inc disclose its waste policy?
Does Cyclerion Therapeutics Inc report according to TCFD requirements?
Does Cyclerion Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Cyclerion Therapeutics Inc disclose energy use targets?
Does Cyclerion Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Cyclerion Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Cyclerion Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.